TAUKLARIFY (Florquinitau F-18) Patent Expiration, LOE Window & CMS Spending

TAUKLARIFY (Florquinitau F-18) by Cerveau Technologies A Lantheus: FDA Orange Book core substance LOE 2035-06-09, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCerveau Technologies A Lantheus
FDA Application & PathwayN220496 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-06-09
Last Listed Patent or Exclusivity Date2035-06-09
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel